Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool March 18, 2009 Brian Orelli	Merck Pummels Pfizer One of these acquisitions is not like the other.
The Motley Fool April 28, 2009 Brian Orelli	The Costs of Being Pfizer With Pfizer having announced its intention to buy Wyeth this quarter, investors may have worried that the negotiating and pre-acquisition planning caused management to be distracted, but that doesn't seem to be the case.
The Motley Fool December 13, 2011 Brian Orelli	Dividend? Buyback? Here's How to Get Both. But will there be enough to replenish the pipeline?
The Motley Fool January 19, 2007 Ryan Fuhrmann	The Best Drug Stock for 2007: Pfizer Investors, this is a great company at a great price.
The Motley Fool December 18, 2008 Brian Orelli	Best Stock for 2009: Pfizer Pfizer's languishing stock price has made the company so much more attractive; it could see a breakout in 2009.
The Motley Fool November 30, 2011 Brian Orelli	3 Things More Important to Pfizer Than Losing Lipitor It's not like we didn't see it coming.
The Motley Fool June 11, 2008 Brian Lawler	Dueling Fools: Pfizer Bear Is Pfizer ready for a comeback? The bearish opinion is that shares may be down, but the bleeding still isn't over.
The Motley Fool February 22, 2007 Brian Lawler	Dueling Fools: Pfizer Bear It's been a blue chip for years, but that doesn't mean it will stay that way forever. It's inconceivable for Pfizer's market capitalization to be valued at $188 billion four years from now, when its revenues could be 40% lower than they are today.
The Motley Fool October 21, 2008 Brian Orelli	The World Is Saving Pfizer The pharma company experienced a double-digit decrease in U.S. sales in the third quarter. Ouch.
The Motley Fool March 9, 2009 Brian Orelli	Merck-Schering Trumps Pfizer-Wyeth The new Merck deal looks a lot better than a combined Pfizer plus Wyeth.
The Motley Fool January 26, 2009 Brian Orelli	Deja Vu All Over Again There's hardly anything to like about Pfizer's deal to buy Wyeth. This is what got Pfizer into its problem in the first place.
The Motley Fool February 22, 2007 Ryan Fuhrmann	Dueling Fools: Pfizer Bull The drug giant has ample firepower. The current company valuation largely ignores Pfizer's upside potential past 2008.
The Motley Fool July 18, 2007 Ryan Fuhrmann	Pfizer Prepares for L-Day Will Pfizer be able to offset the looming loss of Lipitor? Investors, take note.
The Motley Fool December 21, 2006 Ryan Fuhrmann	Dueling Fools: Merck Bear Investors, because of its recent run-up, the risk/reward tradeoff is not very compelling. There are safer, more lucrative ways to invest in the space.
The Motley Fool November 2, 2011 Brian Orelli	Lipitor Loss Looming, Pfizer Shines Good thing it's already priced in.
The Motley Fool April 20, 2007 Ryan Fuhrmann	Discerning Pfizer's Pfuture The company is undergoing a transformation, but that doesn't mean it isn't worth a look from investors.
The Motley Fool May 4, 2011 Brian Orelli	For Pfizer, Breaking Up Is Hard to Do CEO Ian Read pushes back the decision on the company's breakup until 2012.
The Motley Fool August 29, 2008 Brian Orelli	Can Health-Care Dividends Hold Up? As many health-care companies' share prices drop, their dividend yields have become strikingly attractive. The big question, though, is whether these dividends can hold up.
The Motley Fool January 23, 2007 Ryan Fuhrmann	Pfizer Pfizzles Through 2006 The company is in a top-line pickle, but it expects things to get better. Current investors are now left standing until a rebound in growth, now targeted for 2009.
The Motley Fool August 30, 2010 Ilan Moscovitz	Pfizer: Dividend Dynamo or Disaster? The stability and growth of Pfizer's dividend will depend on its ability to continue to develop and grow its pipeline of drugs and successfully integrate Wyeth.
The Motley Fool December 7, 2010 Brian Orelli	How Pfizer's New Chief Can Right the Ship Bigger is not always better.
The Motley Fool November 7, 2011 Tamara Rutter	It Pays to Invest Like a Dog Find out how the Dow's best dividend stocks can work for you.
The Motley Fool December 16, 2008 Brian Orelli	Pfizer Keeps the Change For the first time in decades, investors won't get a dividend increase.
The Motley Fool January 14, 2008 Brian Lawler	Worst Stock for 2008: Pfizer This analyst thinks that Pfizer is a good company, but a bad stock for 2008.
The Motley Fool June 15, 2006 Selena Maranjian	My Dividends Are Bigger Than Yours Your yield may be 2% when mine is a whopping 13%. Here's the secret.
The Motley Fool September 11, 2007 Brian Lawler	Looking Forward at Pfizer With generic competition on the way for Pfizer's top drug, Lipitor, the company stepped up to the podium at the Bear Stearns Healthcare Conference this week to let investors know its plans.
The Motley Fool February 20, 2010 Selena Maranjian	My Big Fat Dividends Stocks like these can plump up your portfolio. Stocks like Pfizer, Nokia, and Bristol-Myers Squibb can offer good yields.
The Motley Fool December 1, 2011 John Grgurich	Pfizer Losing Lipitor Patent: What Investors Need to Know The patent ends today.
The Motley Fool May 3, 2006 Selena Maranjian	When Dividends Are Dicey A hefty dividend yield isn't always something investors can count on.
The Motley Fool September 30, 2010 Brian Orelli	Chief Justice Roberts Sold Pfizer. Should You? Maybe, but not for the same reason.
The Motley Fool October 20, 2008 Brian Orelli	Foolish Forecast: Will Pfizer Flounder Through Another Quarter? Pharmaceutical giant Pfizer releases earnings tomorrow morning. Let's take a look at what the numbers might say and, more importantly, what management might be able to say to get this stock out of its drug-induced coma.
The Motley Fool June 14, 2007 Ryan Fuhrmann	Dueling Fools: GlaxoSmithKline Bear Glaxo is definitely a safe bet in the industry, and Avandia concerns have brought the share levels to even more reasonable levels. But investors can find the risk/reward trade-off even more compelling in other names.
The Motley Fool March 23, 2011 Todd Wenning	Dividend Report Card: Pfizer Investors considering Pfizer as a dividend play should decide if the combination of 4% current yield and low- to mid-single-digit dividend growth potential is a better deal than other pharmaceutical shares are offering.
The Motley Fool August 12, 2010 Brian Orelli	Pfizer: Strengths, Weaknesses, Opportunities, Threats Knowing them all makes it easier to judge an investment.
The Motley Fool February 22, 2007 Ryan Fuhrmann	Dueling Fools: Pfizer Bull Rebuttal The patent expirations are an issue, but the cash is what's really important. Investors, take note.
The Motley Fool May 4, 2010 Brian Orelli	Earnings Growth Trumps Revenue Growth, Except Here A solid quarter for Pfizer, but is there more in the tank?
The Motley Fool August 26, 2010 Jordan DiPietro	Pfizer's Dividends May Not Last Forever Pfizer, which operates in the pharmaceuticals industry, currently pays a dividend of 4.5%. But what's more important than the dividend itself is Pfizer's ability to keep that that cash rolling.
The Motley Fool April 21, 2008 Brian Lawler	Pfizer Is Still Floundering Generic competition keeps pounding away at its sales and profits.
The Motley Fool June 27, 2005 Brian Gorman	Pfizer's Controversial Pairing The pharmaceutical's strategy of combining an experimental medicine with Lipitor will likely come under increasing fire. Investors, take note.
The Motley Fool December 4, 2008 Brian Orelli	Pfizer Blows Statin Smoke Pfizer presents some mildly persuasive numbers to try to win back customers for Lipitor.
The Motley Fool June 30, 2010 Brian Orelli	Is Bristol-Myers Squibb a Buy? Bristol-Myers is a better buy than Eli Lilly for one major reason: its resources.
The Motley Fool April 30, 2008 Brian Lawler	Pfizer Protects Profitable Patent The courts uphold a key patent on Pfizer's top drug.
The Motley Fool January 12, 2012 Brian Orelli	What to Look For From Pfizer in 2012 Leaner? Yes. Meaner? We'll see.
The Motley Fool December 12, 2008 Rich Smith	This Just In: Upgrades and Downgrades Soleil Securities hands out "buy" ratings to Sepracor, Cephalon, Endo Pharm, and Pfizer.
The Motley Fool January 25, 2008 Selena Maranjian	Optimizing Dividends Look for solid and growing yields -- especially when stock prices fall.
The Motley Fool October 19, 2009 Brian Orelli	Foolish Forecast: A Last Look at "Mini" Pfizer In advance of Pfizer's last earnings report before their acquisition of Wyeth, analysts expect a drop in sales and a bigger bottom line decrease.
The Motley Fool April 5, 2005 Stephen D. Simpson	Pfizer Pfaces Its Pfuture Analysts and investors seem happy with Pfizer's long-term strategy. Should they be?
The Motley Fool November 10, 2010 Selena Maranjian	Get Your Big Yields the Right Way Some "income funds" offer less income than you'd think.
The Motley Fool June 19, 2008 Brian Lawler	Pfizer's Small Lipitor Win Pfizer and the most prolific challenger of its Lipitor patents, Indian generic-drug manufacturer Ranbaxy, settle the vast majority of their litigation.
The Motley Fool January 10, 2007 John Reeves	Is Your Stock a Dog? A dividend yield can be a very misleading ratio, and when it comes to identifying stable companies that deliver regular and growing cash flows, you must look deeper than just a single metric.